Showing 3021-3030 of 5646 results for "".
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Oculis Announces that OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Primary Endpoints in Phase 3 OPTIMIZE Trialhttps://modernod.com/news/oculis-announces-that-ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-primary-endpoints-in-phase-3-optimize-trial/2481769/Oculis announced positive topline results from its phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical Optireach formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery. OPTI
- Regeneron Expects FDA Decision on High-Dose Aflibercept in Third Quarterhttps://modernod.com/news/regeneron-expects-fda-decision-on-high-dose-eylea-in-third-quarter/2481766/During its second quarter conference call, Regeneron said it anticipates the FDA will take action on its biologics license application (BLA) for high-dose aflibercept during the third quarter. In June, citing "an ongoing review of inspection findings at a third-party filler,"
- Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-Based Point-of-Care (T-POC) Quantitative Testing Platformhttps://modernod.com/news/versea-ophthalmics-commences-phase-1-launch-of-novel-tear-based-point-of-care-t-poc-quantitative-testing-platform/2481745/Verséa Ophthalmics announced the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management o
- Study: Dietary Oral Zeaxanthin Decreases the Progression of Wet AMDhttps://modernod.com/news/study-dietary-oral-zeaxanthin-decreases-the-progression-of-wet-amd/2481741/Data published in the peer-reviewed journal Ophthalmology and Therapy confirmed both an earlier comparative
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenseshttps://modernod.com/news/euclid-announces-abb-optical-group-as-licensed-manufacturer-and-distributor-of-euclid-ortho-k-lenses/2481691/Euclid Vision has announced that ABB Optical Group is now a licensed manufacturer and distributor of the company’s Ortho-K lenses. Financial terms of the deal were not disclosed. ABB, which Euclid says is the largest distributor of soft lenses in the United States,
- Prevent Blindness Launches Multiple Efforts to Provide Education and Resources on the Effects of Vision Loss and Blindness on Mental Healthhttps://modernod.com/news/prevent-blindness-launches-multiple-efforts-to-provide-education-and-resources-on-the-effects-of-vision-loss-and-blindness-on-mental-health/2481658/Nonprofit group Prevent Blindness is raising awareness on the impact of vision Impairment on mental wellbeing through upcoming focus on Eye Health Summit presentations and web resources. "Because individuals with vision loss can experience a higher prevalence of depres